Doxorubicin-induced hyperpigmentation.
A 39-year-old man with human immunodeficiency virus infection and Kaposi sarcoma on HAART therapy and doxorubicin presented in 2007 with a hyperpigmented tongue. Physical examination also showed hyperpigmented patches on the mucosal aspects of the lips and longitudinal dark bands on multiple nails. A skin biopsy specimen showed pigmentary alteration. Such hyperpigmentation has been described in numerous case reports and case series and has been reported to resolve within weeks to months of cessation of doxorubicin.
Abbasi
Naheed R
NR
Department of Dermatology, New York University, USA.
Wang
Nadia
N
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D002219:Carbamates / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects* / Q000627:therapeutic use; D004338:Drug Combinations; D005663:Furans; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D008047:Lip Diseases / Q000139:chemically induced*; D008297:Male; D008548:Melanosis / Q000139:chemically induced*; D009264:Nails, Malformed / Q000139:chemically induced*; D010755:Organophosphates / Q000627:therapeutic use; D019438:Ritonavir / Q000627:therapeutic use; D012514:Sarcoma, Kaposi / Q000150:complications / Q000188:drug therapy*; D013449:Sulfonamides / Q000627:therapeutic use; D014060:Tongue Diseases / Q000139:chemically induced*; D015215:Zidovudine / Q000627:therapeutic use; D000099227:Abacavir
D019380:Anti-HIV Agents; D000970:Antineoplastic Agents; D002219:Carbamates; D004317:Doxorubicin; D004338:Drug Combinations; D005663:Furans; D019259:Lamivudine; D010755:Organophosphates; D019438:Ritonavir; D013449:Sulfonamides; D015215:Zidovudine; C418262:abacavir, lamivudine, and zidovudine drug combination; D000099227:Abacavir; C426859:fosamprenavir